A Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid Tumors
Eli Lilly and Company
Eli Lilly and Company
Verastem, Inc.
Servier
Pfizer
Bristol-Myers Squibb
Merck Sharp & Dohme LLC
Alterome Therapeutics, Inc.
Pfizer
Tizona Therapeutics, Inc
Revolution Medicines, Inc.
Eli Lilly and Company
Eli Lilly and Company
Merck KGaA, Darmstadt, Germany